This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fernandes, P B
Right arrow Articles by Gade, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernandes, P B
Right arrow Articles by Gade, E

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1986 December; 30(6): 865-873

In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

P B Fernandes, R Bailer, R Swanson, C W Hanson, E McDonald, N Ramer, D Hardy, N Shipkowitz, R R Bower and E Gade

ABSTRACT

The in vitro and in vivo antibacterial activity of A-56268 (TE-031), the 6-O-methyl derivative of erythromycin, was compared with those of erythromycin and other reference drugs. A-56268 had the same spectrum of antibacterial activity as erythromycin. A-56268 was generally 1 log2 dilution more potent or equal to erythromycin against all organisms except haemophilus influenzae and Propionibacterium acnes, for which A-56268 was 1 log2 dilution and 3 log2 dilutions, respectively, less potent. The MBC of A-56268 and erythromycin was not significantly different from the MIC against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus epidermidis, and H. influenzae but was more than 2 log2 dilutions higher than the MICs for some Staphylococcus aureus strains. Human serum at a concentration of 50% did not change the in vitro potency of A-56268 or erythromycin. A-56268 was similar to erythromycin in being more active at pH 8.0 than at the physiologic pH of 7.3. The activity of A-56268 was synergistic with sulfamethoxazole against 4 of 12 strains of H. influenzae. In mouse protection tests, when administered orally A-56268 was more potent than erythromycin against H. influenzae, S. pyogenes, S. pneumoniae, and S. aureus. After subcutaneous administration the potencies of A-56268 and erythromycin were not statistically different from each other. A-56268 was more potent than erythromycin against Legionella infection in guinea pigs. The concentration of A-56268 in the serum and lung was higher than that of erythromycin after intraperitoneal administration. In A-56268 in the serum and lung was higher than that of erythromycin after intraperitoneal administration. In mice, the peak levels in serum of A-56268 and erythromycin were similar after subcutaneous administration and seven times higher for A-56268 after oral administration. The serum half-life of A-56268 was approximately twice that of erythromycin after administration by both routes.

Antimicrob Agents Chemother. 1986 December; 30(6): 865-873




This article has been cited by other articles:

  • Abduljalil, K., Kinzig, M., Bulitta, J., Horkovics-Kovats, S., Sorgel, F., Rodamer, M., Fuhr, U. (2009). Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration. Antimicrob. Agents Chemother. 53: 2892-2901 [Abstract] [Full Text]  
  • Hardy, R. D., Rios, A. M., Chavez-Bueno, S., Jafri, H. S., Hatfield, J., Rogers, B. B., McCracken, G. H., Ramilo, O. (2003). Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of Mycoplasma pneumoniae-Induced Pneumonia. Antimicrob. Agents Chemother. 47: 1614-1620 [Abstract] [Full Text]  
  • Wootton, M., Bowker, K. E., Janowska, A., Holt, H. A., MacGowan, A. P. (1999). In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and {beta}-haemolytic streptococci. J Antimicrob Chemother 44: 445-453 [Abstract] [Full Text]  
  • Johnson, M. M., Hill, S. L., Piddock, L. J. V. (1999). Effect of Carbon Dioxide on Testing of Susceptibilities of Respiratory Tract Pathogens to Macrolide and Azalide Antimicrobial Agents. Antimicrob. Agents Chemother. 43: 1862-1865 [Abstract] [Full Text]  
  • Bergman, K. L., Olsen, K. M., Peddicord, T. E., Fey, P. D., Rupp, M. E. (1999). Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates of Haemophilus influenzae and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 1291-1293 [Abstract] [Full Text]  
  • Mory, F., Lozniewski, A., David, V., Carlier, J. P., Dubreuil, L., Leclercq, R. (1998). Low-Level Vancomycin Resistance in Clostridium innocuum. J. Clin. Microbiol. 36: 1767-1768 [Abstract] [Full Text]  
  • Higa, F., Kusano, N., Tateyama, M., Shinzato, T., Arakaki, N., Kawakami, K., Saito, A. (1998). Simplified Quantitative Assay System for Measuring Activities of Drugs against Intracellular Legionella pneumophila. J. Clin. Microbiol. 36: 1392-1398 [Abstract] [Full Text]  
  • Weber, J., Leung, J., Swanson, S., Idler, K., McAlpine, J. (1991). An erythromycin derivative produced by targeted gene disruption in Saccharopolyspora erythraea. Science 252: 114-117 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»